MERIDIAN BIOSCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Meridian Bioscience, Inc. To Contact The Firm

NEW YORK, July 13, 2017

The investigation focuses on whether the Company and its executives violated federal securities laws.  Specifically, on July 13, 2017, the U.S. Food and Drug Administration ("FDA") issued a press release regarding Meridian's subsidiary, Magellan Diagnostics ("Magellan").  The FDA stated, in part, that an on-site inspection of Magellan's facility in North Billerica, Massachusetts had identified nine observations that could potentially be violations of federal law.  Furthermore, the FDA stated that it will carefully review the evidence to determine if further action is necessary.

If you invested in Meridian stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/VIVO.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26^th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.